144 related articles for article (PubMed ID: 17519884)
1. Intravenous azacitidine for MDS.
Gore SD
Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
[No Abstract] [Full Text] [Related]
2. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
3. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
4. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
6. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
7. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
8. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine.
Issa JP; Kantarjian H
Nat Rev Drug Discov; 2005 May; Suppl():S6-7. PubMed ID: 15962522
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
12. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
[No Abstract] [Full Text] [Related]
13. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Tomonaga M; Kamae I
Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Tallman MS; Gore SD;
Br J Haematol; 2014 Aug; 166(3):352-9. PubMed ID: 24712482
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and cost-effectiveness of at home azacitidine administration.
Sampol A; Delgado E; López B
Med Clin (Barc); 2017 Sep; 149(5):224-225. PubMed ID: 28610766
[No Abstract] [Full Text] [Related]
16. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829
[No Abstract] [Full Text] [Related]
18. Myelodysplastic syndromes (MDS).
Klimek V
Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
[No Abstract] [Full Text] [Related]
19. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]